Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine for cognitive deficits in adolescents with neurofibromatosis type 1 (NF1-EXCEL)
2013-003405-26Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lamotrigine in neurofibromatosis type 1 (NF1) (2 arms), sponsored by Erasmus MC. Primary endpoint: Performance IQ (WISC-III). Started Sep 2013; status: active.
02
Drugs
lamotrigine
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on 2013-003405-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003405-26.